首页> 外文OA文献 >Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.
【2h】

Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.

机译:溃疡性结肠炎中舒马沙林保留灌肠:一项双盲试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thirty-four patients with ulcerative colitis completed a double-blind assessment comparing the efficacy of two weeks of treatment with nightly retention enemas containing 3 g sulphasalazine or placebo. Symptom grading, sigmoidoscopic appearance, rectal biopsy specimens, and diary records were used to assess benefit and side effects. The active drug conferred significant benefit compared with placebo as shown by several criteria, but this benefit was confined to patients not already taking sulphasalazine by mouth. Overall assessment showed improvement in 11 of the 16 patients (70%) given the active treatment but in only two of the 18 (11%) given placebo. No side effects attributable to the drug were observed, even in patients previously intolerant to oral preparations. The logical therapeutic role of sulphasalazine enemas in ulcerative colitis would appear to be in patients who experience side effects such as nausea, abdominal discomfort, or headaches when taking the drug by mouth.
机译:34例溃疡性结肠炎患者完成了一项双盲评估,比较了含3 g柳氮磺吡啶或安慰剂的夜间保留灌肠治疗两周的疗效。症状分级,乙状结肠镜外观,直肠活检标本和日记记录用于评估获益和副作用。如多项标准所示,与安慰剂相比,该活性药物具有明显的益处,但这种益处仅限于尚未通过口服服用柳氮磺吡啶的患者。总体评估显示,接受积极治疗的16例患者中有11例(70%)有所改善,但接受安慰剂的18例中只有2例(11%)有所改善。没有观察到可归因于该药物的副作用,即使在以前不耐受口服制剂的患者中也是如此。柳氮磺胺吡啶类灌肠剂在溃疡性结肠炎中的合乎逻辑的治疗作用似乎是在口服服用药物时出现恶心,腹部不适或头痛等副作用的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号